Human Cell Expression Cytokines Functional Activities
Functional activities of human proteins depend on proper folding, phosphorylation, disulfide bridge formation, and proteolytic processing or appropriate glycosylation. Ideally, recombinant human proteins produced in human cells are more authentic in terms of both physical properties and biochemical functions. However, the current process of human cell expression requires a large quantity of DNA and medium supplemented with bovine serum. Hence, it is often a daunting task to produce sufficient amount of high quality proteins for drug discovery or diagnostic development (1-100mg) at acceptable cost. United States Biological is now supplying a high yield, cost-effective and versatile system to produce active recombinant human proteins in a human 293-cell expression system to meet the special needs of the broad scientific community and drug discovery industry. In this system, we have broken key bottleneck steps to increase protein production and reduce cost, including
1. Engineered human cell line adapted to suspension for growth in serum-free and chemically defined medium 2. Proprietary expression vectors driven by strong promoters and signal peptides 3. Large scale transient expression with small quantity of DNA 4. Rapid creation of stable human cell lines and adaptation to serum-free medium 5. Short time to scale up production 6. Efficient tag or tag-free purification
Using this expression system, we have produced a large number of highly active human cytokines, kinases and phosphatases. Our technology is particularly suitable for the production of high-authenticity human proteins in medium scale for research and diagnostic reagents, drug screening targets, and therapeutic proteins for preclinical evaluation. Key differences of recombinant human protein production in different systems are illustrated below:
| Expression system |
E. coli |
Insect cell |
CHO cell |
Human cell |
| Protein folding |
+ |
++ |
+++ |
++++ |
| Phosphorylation |
- |
++ |
+++ |
++++ |
| Proteolytic processing |
- |
+ |
+++ |
++++ |
| Glycosylation |
- |
Poor |
Not human-like |
Authentic |
Cytokines are a group of proteins and polypeptides that organisms use as signaling molecules. Most cytokines are glycoproteins less than 30kD in size and bind to specific, high-affinity cell surface receptors. Due to their central role in the immune system, cytokines are involved in a variety of immunological, inflammatory and infectious diseases and widely used in research, diagnostics and therapeutics. Currently, these proteins are predominantly produced in non-human cells (e.g. E. coli, SF9, CHO) and therefore lack authenticity due to the absence of physiologically relevant glycosylation. In addition, a number of important cytokines are not commercially available due to inadequate proteolytic processing, protein folding or other post-translational modifications that occur in the non-human cell expression systems. United States Biological is now supplying recombinant cytokines based on human cell expression technology, for the scalable production of human cytokines. These authentic cytokines are preferred reagents for stem cell, cancer, and inflammation research, and also antibody development.
Cytokines produced in E. coli are not glycosylated and may expose cryptic or normally hidden epitopes. Similarly, cytokines produced in SF9 or CHO cells have post-translational modifications that are not human-like. Because of these factors, antibodies may have different affinities depending on whether they were created from human cell expressed protein antigens or non-human cell expressed protein antigens. Indeed, Western blot analysis shows that monoclonal antibodies raised against a full-length protein from non-human cells poorly recognize the recombinant human cytokines produced in human cells using this human cell expression technology. In contrast, these antibodies are highly reactive to the proteins that may correspond to micro-aggregates. These results indicate that recombinant cytokines from a human cell expression system are highly preferred antigens to raise antibodies as well as use as standards in ELISA assays.
IL-23 (I8443-40G, Interleukin 23, Recombinant, Human (IL-23) (Human 293 Cells)) Currently, commercially available recombinant IL-23 cytokine is produced as a heterodimeric or fusion protein from an insect cell expresion system. United States Biological has IL-23 available that is produced in a stable cell culture of engineered human HEK293 cells. The protein is expressed as a disulfide-linked dimer of 55kD and, due to the scalability of the stable culture, can be cost-effectively produced. (Fig. 1). 
Figure 1. Highly purified glycosylated, dimeric recombinant human IL-23 (I8443-40G) expressed in an HEK293 human cell expression system. Lane 1: MW standards, Lane 2: non-reducing conditions, Lane 3: reducing conditions.
IL-17-producing CD4+ T cells (Th17 cells) have been identified as a unique subset of T helper cells that develop along a pathway that is distinct from the Th1 and Th2-cell differentiation pathways. This finding has provided exciting new insights into immunoregulation, host defense and the pathogenesis of autoimmune diseases. Recently it has been shown that TGF-s1 , IL-1s, IL-6 and IL-23 are important in driving human Th17 differentiation. The bioactivities of IL-23 from human and insect cells were first determined by the dose-dependent secretion of IL-17 from mouse splenocytes activated with 10 ng/ml PMA, which shows that IL-23 (Human 293 Cells) is ten fold more active. (Fig. 2).
 Figure 2. IL-23 (I8443-40G) activities determined by the dose-dependent secretion of IL-17 from mouse splenocytes activated with 10ng/ml PMA.
The activities were further assayed with human CD4+ cells isolated from a healthy donor and stimulated with 10ug/ml plate bound anti-CD3 and 10ug/ml soluble anti-CD28 in the presence of Th17 polarizing cytokines. After 5 days, the supernatants were harvested and IL-17 was measured by ELISA. The results show that I8443-40G is 100-fold more potent for inducing IL-17 secretion in two independent studies, maximum induction was achieved with 0.1 ng/ml I8443-40G vs. 10ng/ml with insect cell-produced IL-23 (Fig. 3). These results demonstrate that authenic human tcell expressed cytokines can induce Th17 cell differentiation at physiologically relevant concentration and may lead to more accurate scientific understanding of human biological process.
Figure 3. IL-23 (I8443-40G) activities determined by the dose-dependent secretion of IL-17 from human CD4+ T cells stimulated with 2mg/ml plate bound anti-CD3 and 1mg/ml soluble anti-CD28 in the presence of Th17 polarizing cytokines.
A rapidly expanding range of human 293 cell expressed cytokines are available from United States Biological. The proteins are manufactured to high quality standards and provide high biological activity, lot-to-lot consistency and low endotoxin levels.
Recombinant Cytokines Expressed in Human 293 Cells
| A2281-45A |
Androgen Receptor Coactivator ARA55, Recombinant, Human ( Transforming Growth Factor beta1-induced Transcript 1, TGFB1I1) (Human 293 Cells) |
| B2553-08B |
Bone Morphogenetic Protein 2, Recombinant, Human (BMP-2) (Human 293 Cells) |
| B2553-20C |
Bone Morphogenic Protein 4, Recombinant, Human (BMP4, DVR4) (Human 293 Cells) |
| C2448-02Q |
CD117, Recombinant, Human (c-kit, Stem Cell Factor, SCF Receptor, Steel Factor Receptor, Mast Cell Growth Factor, MGF) (Human 293 Cells) |
| E3455-07B |
Erythropoietin, Recombinant, Human (EPO) (Human 293 Cells) |
| F4211-51 |
Fibroblast Growth Factor 8b, Recombinant, Human (FGF8b) (Human 293 Cells) |
| F4600-10C |
Flt3 Ligand, Recombinant, Human (Fms-like Tyrosine Kinase 3 Ligand, flk2 Ligand) (Human 293 Cells) |
| G8950-02C |
Granulocyte Colony Stimulating Factor, Recombinant, Human (G-CSF) (Human 293 Cells) |
| G9000-07A |
Growth Hormone, Recombinant, Human (hGH) (Human 293 Cells) |
| H2005-02A |
Hepatocyte Growth Factor, Recombinant, Human (HGF, Scatter Factor, SF, Hepatopoietin A) (Human 293 Cells) |
| I0945-06A |
Inhibin A, beta, Recombinant, Human (Activin) (Human 293 Cells) |
| I7661-64D |
Interferon alpha 2b, Recombinant, Human (IFNa2b) (Human 293 Cells) |
| I7662-06C |
Interferon alpha A (alpha 2a), Recombinant, Human (IFNaA, IFNa2a) (Human 293 Cells) |
| I7663-07A1 |
Interleukin 1 beta, Recombinant, Human (IL-1b) (Human 293 Cells) |
| I7663-26A4 |
Interleukin 2, Recombinant, Human (IL-2) (Human 293 Cells) |
| I7663-37E |
Interleukin 3, Recombinant, Human (IL-3) (Human 293 Cells) |
| I8426-04D |
Interleukin 4, Recombinant, Human (IL-4, B Cell Stimulatory Factor 1, BSF1, Binetrakin, HCGF, Hodgkin's Cell Growth Factor, IA Inducing Factor, Lymphocyte Stimulatory Factor 1, Macrophage Fusion Factor, Mast Cell Growth Factor 2, MCGF2, MFF, MGC79402, Pitrakinra, T Cell Growth Factor 2, TCGF2) (Human 293 Cells) |
| I8428-02B4 |
Interleukin 6, Recombinant, Human (IL-6, B cell Stimulatory Factor 2, BSF2, Cytotoxic T cell Differentiation Factor, CTL Differentiation Factor, CDF, Hepatocyte Stimulating Factor, HSF, Hybridoma Growth Factor, HGF, Hybridoma Plasmacytoma Growth Factor, HPGF, Interferon beta 2, IFNB2) (Human 293 Cells) |
| I8432-13P |
Interleukin 10, Recombinant, Human (IL-10, Cytokine Synthesis Inhibitory Factor, CSIF) (Human 293 Cells) |
| I8434-01B |
Interleukin 12, Recombinant, Human (IL-12, Cytotoxic Lymphocyte Maturation Factor 1, CTL Maturation Factor, TcMF, CLMF p35, Natural Killer Cell Stimulatory Factor 1, NFSK1, p35, T cell Stimulating Factor, TSF) (Human 293 Cells) |
| I8439-10D |
Interleukin 17, Recombinant, Human (IL-17, CTLA8, IL-17A, Interleukin-17A precursor, Cytotoxic T-lymphocyte-associated antigen 8) (Human 293 Cells) |
| I8439-28B |
Interleukin 17F, Recombinant, Human (IL-17F) (Human 293 Cells) |
| I8443-40G |
Interleukin 23, Recombinant, Human (IL-23) |
| K0201-01C |
Keratinocyte Growth Factor, Recombinant Human (KGF, Fibroblast Growth Factor 7, FGF-7) (Human 293 Cells) |
| L1662-94 |
Lefty B, Recombinant, Human (Left-Right Determination, Factor B, LEFTB, LEFTY1) (Human 293 Cells) |
| M1201-01D |
Macrophage Colony Stimulating Factor, Recombinant, Human (M-CSF, CSF-1, Lanimostim, Macrophage colony-stimulating factor 1 precursor, MCSF, MGC31930) (Human 293 Cells) |
| N3100-05E |
Noggin, Recombinant, Human (Human 293 Cells) |
| O6500-05A |
Oncostatin M, Recombinant, Human (OSM) (Human 293 Cells) |
| T8250-26A |
Transforming Growth Factor beta2 Receptor, Recombinant, Human (TGFb2R) (Human 293 Cells) |
| T8250-45E |
Transforming Growth Factor beta 3, Recombinant, Human (TGFb3) (Human 293 Cells) |
| T9160-02S |
Tumor Necrosis Factor alpha, Recombinant, Human (TNFa) (Human 293 Cells) |
| V2110-04H |
Vascular Endothelial Growth Factor, Recombinant, Human (VEGF) (Human 293 Cells) |
| V2110-15C |
Vascular Endothelial Growth Factor 165, Recombinant, Human (VEGF165) (Human 293 Cells) |
|